Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:class |
gptkb:pharmaceuticals
gptkb:immunotherapy targeted therapy |
| gptkbp:clinical_trial |
Phase 2
minimal residual disease B-cell precursor acute lymphoblastic leukemia NCT02000427 NCT02013167 NCT02013180 NCT02013193 |
| gptkbp:developed_by |
gptkb:Amgen
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:duration |
28 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Blincyto
|
| gptkbp:indication |
minimal residual disease positive acute lymphoblastic leukemia
|
| gptkbp:ingredients |
blinatumomab
|
| gptkbp:invention |
US 10,000,000 B2
US 8,703,652 B2 US 9,013,155 B2 US 9,404,127 B2 US 9,517,221 B2 |
| gptkbp:marketed_as |
gptkb:Blincyto
|
| gptkbp:mechanism_of_action |
engages T-cells to target cancer cells
bispecific T-cell engager |
| gptkbp:patient_population |
pediatric patients
adult patients |
| gptkbp:provides_guidance_on |
ASCO guidelines
NCCN guidelines ECOG guidelines |
| gptkbp:reimbursement |
covered by Medicaid
covered by Medicare covered by private insurance |
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_measures |
blood tests
liver function tests neurological assessments renal function tests cytokine levels |
| gptkbp:service_frequency |
continuous infusion
|
| gptkbp:side_effect |
gptkb:anemia
fatigue headache nausea fever vomiting diarrhea rash chills infections thrombocytopenia cytokine release syndrome infection risk neurotoxicity hypotension neutropenia neurological events dyspnea hypersensitivity reaction |
| gptkbp:storage |
refrigerated
|
| gptkbp:structure |
C_640_ H_1000_ N_200_ O_200_ S_2
|
| gptkbp:targets |
gptkb:CD_format
gptkb:CD19 |
| gptkbp:used_for |
treatment of acute lymphoblastic leukemia
|
| gptkbp:bfsParent |
gptkb:Amgen
|
| gptkbp:bfsLayer |
4
|